A Phase 1a/b Dose-Finding Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 19-1458
More information available at ClinicalTrials.gov: NCT04068896
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers